Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and arterial effects of canakinumab in intermittent claudication
2012-001427-12Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans comparing Canakinumab arm with Placebo arm (2 arms). Primary endpoint: Mean vessel wall volume. Started Feb 2013; status: terminated.
02
Drugs
canakinumab
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2012-001427-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001427-12.